Deruxtecan |
| Katalog-Nr.GC35840 |
Deruxtecan ist ein ADC-Drug-Linker-Konjugat, das aus einem Derivat von DX-8951 (DXd) und einem Amaleimid-GGFG-Peptid-Linker besteht und zur Synthese von DS-8201 und U3-1402 verwendet wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1599440-13-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Deruxtecan, a toxin and linker moiety of DS-8201, is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1. Drug-linker conjugates for ADC[1]
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].
[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1. [2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *